Literature DB >> 10528197

Quantitative alleles of CR1: coding sequence analysis and comparison of haplotypes in two ethnic groups.

L Xiang1, J R Rundles, D R Hamilton, J G Wilson.   

Abstract

The quantitative expression of complement receptor type 1 (CR1) on erythrocytes is regulated by two CR1 alleles that differ in having genomic HindIII fragments of either 7.4 or 6.9 kb and that determine high (H allele) or low (L allele) CR1 expression, respectively, across a 10-fold range. To investigate whether the product of the L allele may contain amino acid substitutions that make it more susceptible to proteolysis, cDNA sequence spanning the CR1 coding region was analyzed in two donors who were homozygous for the H and L alleles and differed by 7-fold in their mean numbers of CR1 per erythrocyte. Sequence differences were detected at 10 nucleotide positions, including 6 that would cause amino acid substitutions. The HindIII RFLP and 3 of the latter 6 sites were analyzed in genomic DNA of 85 Caucasians and 75 African Americans; sites encoding the other amino acid substitutions were analyzed less extensively. Two major haplotypes defined prototypic H and L alleles in both ethnic groups, suggesting that these alleles existed before the African and European populations diverged. Decreased erythrocyte CR1 expression is associated with impaired clearance of immune complexes from blood. Persistence of the L allele in all populations that have been analyzed may suggest a compensatory survival advantage, perhaps related to malaria or another infectious disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10528197

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  28 in total

1.  Extensive genomic and functional polymorphism of the complement control proteins.

Authors:  Craig A McLure; Joseph F Williamson; Louise A Smyth; Suraksha Agrawal; Susan Lester; John A Millman; Peter J Keating; Brent J Stewart; Roger L Dawkins
Journal:  Immunogenetics       Date:  2005-11-11       Impact factor: 2.846

2.  Plasmodium falciparum uses a key functional site in complement receptor type-1 for invasion of human erythrocytes.

Authors:  Wai-Hong Tham; Christoph Q Schmidt; Richard E Hauhart; Mara Guariento; Patience B Tetteh-Quarcoo; Sash Lopaticki; John P Atkinson; Paul N Barlow; Alan F Cowman
Journal:  Blood       Date:  2011-06-17       Impact factor: 22.113

3.  Erythrocyte complement receptor 1 (CR1) expression level is not associated with polymorphisms in the promoter or 3' untranslated regions of the CR1 gene.

Authors:  I A Cockburn; J A Rowe
Journal:  Int J Immunogenet       Date:  2006-02       Impact factor: 1.466

4.  Minimal association of common red blood cell polymorphisms with Plasmodium falciparum infection and uncomplicated malaria in Papua New Guinean school children.

Authors:  Enmoore Lin; Livingstone Tavul; Pascal Michon; Jack S Richards; Elijah Dabod; James G Beeson; Christopher L King; Peter A Zimmerman; Ivo Mueller
Journal:  Am J Trop Med Hyg       Date:  2010-10       Impact factor: 2.345

5.  A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b.

Authors:  Daniel J Birmingham; Wei Chen; Grace Liang; Holly C Schmitt; Katie Gavit; Haikady N Nagaraja
Journal:  Immunology       Date:  2003-04       Impact factor: 7.397

6.  Complement receptor 1 is the host erythrocyte receptor for Plasmodium falciparum PfRh4 invasion ligand.

Authors:  Wai-Hong Tham; Danny W Wilson; Sash Lopaticki; Christoph Q Schmidt; Patience B Tetteh-Quarcoo; Paul N Barlow; Dave Richard; Jason E Corbin; James G Beeson; Alan F Cowman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

7.  A complement receptor-1 polymorphism with high frequency in malaria endemic regions of Asia but not Africa.

Authors:  B N Thomas; B Donvito; I Cockburn; T Fandeur; J A Rowe; J H M Cohen; J M Moulds
Journal:  Genes Immun       Date:  2005-02       Impact factor: 2.676

Review 8.  Blood groups and malaria: fresh insights into pathogenesis and identification of targets for intervention.

Authors:  J Alexandra Rowe; D Herbert Opi; Thomas N Williams
Journal:  Curr Opin Hematol       Date:  2009-11       Impact factor: 3.284

9.  Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.

Authors:  Christoph Q Schmidt; Markus J Harder; Eva-Maria Nichols; Mario Hebecker; Markus Anliker; Britta Höchsmann; Thomas Simmet; Ádám I Csincsi; Barbara Uzonyi; Isabel Y Pappworth; Daniel Ricklin; John D Lambris; Hubert Schrezenmeier; Mihály Józsi; Kevin J Marchbank
Journal:  Immunobiology       Date:  2016-01-06       Impact factor: 3.144

10.  Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Tommaso Rondelli; Antonio M Risitano; Régis Peffault de Latour; Michela Sica; Benedetta Peruzzi; Patrizia Ricci; Wilma Barcellini; Anna Paola Iori; Carla Boschetti; Veronica Valle; Veronique Frémeaux-Bacchi; Maria De Angioletti; Gerard Socie; Lucio Luzzatto; Rosario Notaro
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.